Phase 4 N=22 Randomized Quadruple-blind Treatment

Efficacy of Resveratrol in Depression

Depression

Bottom Line

View on ClinicalTrials.gov: NCT03384329 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2020

Primary outcome: Primary: Change in Total HDRS-17 Score From Baseline to Week 4 — -7.2; -9.9 score on a scale

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Resveratrol Pill (Drug); Placebos (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Russian Academy of Medical Sciences
Primary completion: Aug 2019

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Total HDRS-17 Score From Baseline to Week 4	-7.2; -9.9	—
PRIMARY Change in SIRT1 Activity From Baseline to Week 4	-0.59; -0.02	—
SECONDARY Change in Total BDI-II Score From Baseline to Week 4	-9.3; -9.7	—

Summary

Patients with depression (target number - 60) receive resveratrol 500 mg or placebo (1:1) each morning daily for 1 month with primary outcome measures of the score change on depression rating scale HDRS-17 and change in SIRT1 activity in the blood measured 4 times over the study period (before, in the middle, after the intervention, and in 2 week follow up).

Eligibility Criteria

Inclusion Criteria (selectively):

MDD recurrent or with single episode with melancholic features or dysthymia (DSM-5);
current depression.

Exclusion Criteria (selectively):

serious or unstable disease;
antidepressants intake.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03384329). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.